MARATTO

article · Egyptian Journal of Veterinary Science

Cardioprotective Effects of Moringa oleifera in Cisplatin-Intoxicated Rats

20242 citationsOpen accessSuez Canal University

Abstract

Cisplatin is an anticancer medication with systemic side effects that limit its use. Moringa oleifera is a medical plant with antioxidant and protective properties. Thus, this study determined the protective impact of M. oleifera against cisplatin-induced cardiotoxicity. The rats were randomly separated into six groups. Group (1) normal rats; groups (2) and (3) received M. oleifera leaf extract orally at 250 and 500 mg/kg b.wt., respectively, for 28 days; and group (4) was given a single dosage of cisplatin at 10 mg/kg b.wt. i.p. on the 20th day of the experiment, while groups (5) and (6) were given orally M. oleifera at the same doses as groups (2) and (3), then cisplatin at a similar dose to group (4). Cisplatin administration resulted in significant cardiac histopathological changes, with markedly increased cardiac markers, oxidative stress markers, and lipid profile, whereas antioxidant markers were dramatically lowered compared with the control group. Administration of M. oleifera improves biochemical and histological parameters in a dose-dependent manner. The current study proposed that Moringa oleifera extract improves changes in biochemical parameters and heart histopathology in cisplatin-intoxicated rats, and it could be used in combination with cisplatin to reduce cardiotoxicity.

Research topics

  • Moringa oleifera research and applications
  • Chemotherapy-induced organ toxicity mitigation
  • Apelin-related biomedical research

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ejvs.2024.296784.2169

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.